# InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Reports Q1 2025 Results, Advances Phase 3 Depression Program and Nears Completion of Phase 2 Anxiety Study

Cybin (NYSE American: CYBN) (Cboe CA: CYBN), a clinical-stage neuropsychiatry company developing next-generation mental health treatments, reported unaudited Q1 2025 results and key program updates. The company gained European Clinical Trial Application and UK MHRA approval to begin EMBRACE, expanding its multinational Phase 3 PARADIGM program of CYB003 for adjunctive treatment of major depressive disorder to approximately 550 participants. The Phase 3 studies target patients with moderate to severe MDD unresponsive to existing antidepressants. Cybin also said its Phase 2 study of CYB004 for generalized anxiety disorder is expected to complete enrollment this month. Management said recent funding positions the company to advance both programs through multiple upcoming inflection points.

 To view the full press release, visit https://ibn.fm/G5r2t

 About Cybin

 Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

 With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

 Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

 NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-cybin-inc-nyse-american-cybn-cboe-ca-cybn-reports-q1-2025-results-advances-phase-3-depression-program-and-nears-completion-of-phase-2-anxiety-study/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/cybin-advances-mental-health-treatments-with-q1-2025-updates-and-program-milestones/1b229aa949886a0e13ad1235ef2d7354) 


Pickup - [https://cannabis.in-focus.news](https://cannabis.in-focus.news/202508/150035-cybin-advances-mental-health-treatments-with-q1-2025-results-and-key-program-updates)

Pickup - [https://themaverickpr.com/services/cannabis-news](https://themaverickpr.com/services/cannabis-news/202508/150033-cybin-advances-mental-health-treatments-with-q1-2025-results-and-key-program-updates)

Pickup - [https://faqstaq.news/news](https://faqstaq.news/news/202508/150287-cybin-inc-q1-2025-results-and-clinical-program-updates-faq)

Pickup - [https://goinvest.com/ibn-faqstaq](https://goinvest.com/ibn-faqstaq/202508/150490-cybin-inc-q1-2025-results-and-clinical-trials-update-faq)
 



[Reddit Post](https://www.reddit.com/r/PsychedelicsNews/comments/1mq5yvx/cybin_advances_mental_health_treatments_with_q1/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/258/14/blurAjKJ.webp)